Dissecting Therapeutic Resistance to ERK Inhibition.

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The Mitogen-Activated Protein Kinase (MAPK) pathway is crucial in melanoma development and is often activated by BRAF mutations.
• Targeted therapies like BRAF and MEK inhibitors show initial efficacy but are limited by acquired resistance.
• ERK1/2 inhibitors, such as SCH772984, show promise in overcoming resistance to upstream MAPK pathway inhibitors.

Purpose of the Study:

• To prospectively model and characterize acquired resistance to the ERK1/2 inhibitor SCH772984.
• To identify the molecular mechanisms underlying resistance to SCH772984 in melanoma models.

Main Methods:

• Long-term exposure of cancer cells to SCH772984 to induce acquired resistance.
• Genetic sequencing to identify mutations in resistant cell lines.
• Structural and biophysical studies to assess drug-target interactions.

Main Results:

• Long-term SCH772984 treatment led to acquired resistance in cancer cells.
• A specific mutation, glycine to aspartic acid at residue 186 (G186D) in the DFG motif of ERK1, was identified as the cause of resistance.
• The G186D mutation was shown to impair the binding of SCH772984 to ERK1.

Conclusions:

• Acquired resistance to SCH772984 can develop through mutations within the ERK1 enzyme.
• A novel mechanism of resistance involves alterations in the DFG motif of ERK1, affecting inhibitor binding.
• Understanding these resistance mechanisms is critical for developing durable therapies for BRAF-mutant melanoma.